Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Cash And Cash Equivalents : $235.8 Mil (As of Jun. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Biohaven Pharmaceutical Holding Co Cash And Cash Equivalents?

Biohaven Pharmaceutical Holding Co's quarterly cash and cash equivalents declined from Dec. 2021 ($171.95 Mil) to Mar. 2022 ($169.07 Mil) but then increased from Mar. 2022 ($169.07 Mil) to Jun. 2022 ($235.81 Mil).

Biohaven Pharmaceutical Holding Co's annual cash and cash equivalents declined from Dec. 2019 ($316.73 Mil) to Dec. 2020 ($132.15 Mil) but then increased from Dec. 2020 ($132.15 Mil) to Dec. 2021 ($171.95 Mil).

Biohaven Pharmaceutical Holding Co Cash And Cash Equivalents Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Cash And Cash Equivalents Chart

Biohaven Pharmaceutical Holding Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash And Cash Equivalents

Get a 7-Day Free Trial

131.47

264.25

316.73

132.15

171.95

Biohaven Pharmaceutical Holding Co Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Cash And Cash Equivalents	Get a 7-Day Free Trial															306.27	501.41	171.95	169.07	235.81

Biohaven Pharmaceutical Holding Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Biohaven Pharmaceutical Holding Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510

Website

https://www.biohavenpharma.com

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

Executives

Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark	officer: VP, Chief Accounting Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic	director	215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Elyse Stock	officer: Chief Medical Officer	215 CHURCH STREET NEW HAVEN CT 06510
James Engelhart	officer: Chief Financial Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten	officer: Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Declan Doogan	director	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs	director, 10 percent owner	111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Kishan Mehta	director	540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Jones William A Jr	officer: CCO-Migraine & Common Disease	NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Kimberly Gentile	officer: VP of Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Robert Berman	officer: Chief Medical Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John Tilton	officer: Chief Commercial Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054